Last reviewed · How we verify
Aldara - Imiquimod 5%
At a glance
| Generic name | Aldara - Imiquimod 5% |
|---|---|
| Sponsor | Sun Pharmaceutical Industries, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma (EARLY_PHASE1)
- Topical Imiquimod Treatment of Oral Dysplasia (PHASE1, PHASE2)
- Basal Cell Carcinoma Chemoprevention Trial (PHASE3)
- A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma (PHASE2)
- Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects (PHASE3)
- Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma (PHASE1, PHASE2)
- A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas (PHASE1)
- A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aldara - Imiquimod 5% CI brief — competitive landscape report
- Aldara - Imiquimod 5% updates RSS · CI watch RSS
- Sun Pharmaceutical Industries, Inc. portfolio CI